So, you know, management of MBL is mostly observation at this point, and that’s really what the paper emphasizes, is that outside of a clinical trial setting, we don’t necessarily need to do any specific interventions other than monitoring for second cancers, infection prophylaxis, and these sorts of things. But I think it really also touches on where we’re heading in the future, where we may be able to intervene early...
So, you know, management of MBL is mostly observation at this point, and that’s really what the paper emphasizes, is that outside of a clinical trial setting, we don’t necessarily need to do any specific interventions other than monitoring for second cancers, infection prophylaxis, and these sorts of things. But I think it really also touches on where we’re heading in the future, where we may be able to intervene early. There’s a discussion in the paper of a very short course of treatment, for example, with acalabrutinib and venetoclax, which is being explored in a clinical trial. The paper also touches on a neoantigen vaccine strategy that we’re pursuing at Dana-Farber and studying in that early intervention setting. So there’s a lot of active research going on in this area.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
